Broadening Bioconjugate Design, Development To Develop Better Medicines

Antibody-drug conjugates (ADCs) are reshaping the landscape of targeted cancer therapy. By merging the precision of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs, ADCs offer a powerful approach to eliminating cancer cells while sparing healthy tissue.

These innovative therapeutics expand the therapeutic window of cytotoxic drugs by selectively delivering them to cells expressing specific tumor antigens recognized by mAbs. The efficacy of ADCs hinges on a complex interplay of factors, including antibody specificity, linker technology, and payload potency, as they interact with the tumor and its microenvironment.

Dr. Petra Dieterich, Senior Vice President and Scientific Leader at Abzena, delves into the intricate world of ADCs and their transformative potential in cancer treatment. Access the full article to explore insights into the latest advancements and future directions of ADCs.